Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $1.6 billion.

  • Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity rose 5825.1% to $1.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $5.9 billion, marking a year-over-year increase of 4887.23%. This contributed to the annual value of $1.4 billion for FY2025, which is 2153.82% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $1.6 billion for Q4 2025, which was up 5825.1% from $1.4 billion recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $1.6 billion in Q4 2025 and a low of $626.3 million during Q4 2023
  • Its 5-year average for Liabilities and Shareholders Equity is $944.7 million, with a median of $839.8 million in 2023.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity plummeted by 2974.83% in 2023, and later surged by 6473.83% in 2025.
  • Arrowhead Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $638.5 million in 2021, then surged by 39.61% to $891.5 million in 2022, then fell by 29.75% to $626.3 million in 2023, then soared by 61.86% to $1.0 billion in 2024, then skyrocketed by 58.25% to $1.6 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.6 billion in Q4 2025, compared to $1.4 billion in Q3 2025 and $1.4 billion in Q2 2025.